Trials / Recruiting
RecruitingNCT07090785
A Study of LY4088044 in Healthy Participants
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants.
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY4088044 | Administered IV |
| DRUG | LY4088044 | Administered SC |
| DRUG | Placebo | Administered IV |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2025-07-24
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2025-07-29
- Last updated
- 2026-03-02
Locations
6 sites across 3 countries: United States, New Zealand, Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07090785. Inclusion in this directory is not an endorsement.